Ditchcarbon
  • Customers
  1. Organizations
  2. Innovent Biologics
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated 6 days ago

Innovent Biologics

Company website

Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2011, the company has rapidly established itself in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions. With a strong presence in major operational regions across Asia and beyond, Innovent is recognised for its robust pipeline of monoclonal antibodies and biosimilars. Their flagship products, including the PD-1 inhibitor Tyvyt, have garnered significant attention for their unique mechanisms of action and efficacy. Innovent's commitment to research and development has positioned it as a key player in the global market, achieving notable milestones such as successful partnerships and regulatory approvals that underscore its reputation for excellence in biopharmaceutical innovation.

DitchCarbon Score

How does Innovent Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

33

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Innovent Biologics's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Let us know if this data was useful to you

Innovent Biologics's reported carbon emissions

In 2023, Innovent Biologics reported total carbon emissions of approximately 15,894,420 kg CO2e. This figure includes 65,170 kg CO2e from Scope 1 emissions and about 15,829,250 kg CO2e from Scope 2 emissions. Notably, the company did not disclose Scope 3 emissions data for this year, although the total emissions reported align with the sum of Scope 1 and Scope 2 emissions. Comparatively, in 2022, Innovent Biologics recorded total emissions of about 22,302,950 kg CO2e, with Scope 1 emissions at 66,740 kg CO2e and Scope 2 emissions at approximately 22,236,210 kg CO2e. This indicates a significant reduction in total emissions from 2022 to 2023. Despite these figures, Innovent Biologics has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from a parent organisation, and all reported figures are directly attributed to Innovent Biologics, Inc. Overall, while Innovent Biologics has made strides in reducing its emissions, the lack of formal climate commitments or reduction targets suggests an area for potential improvement in their sustainability strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920222023
Scope 1
39,400
00,000
00,000
Scope 2
39,400
00,000,000
00,000,000
Scope 3
-
-
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Innovent Biologics's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Innovent Biologics is in CN, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Innovent Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

China Resources Double-Crane Pharmaceutical Co.,Ltd.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

China Biopharmaceuticals Holdings, Inc.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Akeso

CN
•
Pharmaceutical Preparation Manufacturing
Updated about 4 hours ago

Guangzhou Gloria Biosciences Co., Ltd.

CN
Updated 9 days ago

Hengrui Pharma

CN
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250731.5
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy